Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785233 | 1.00 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL186444 | 0.89 | TSHR (0.40) | L3MBTL1ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL186933 | 0.89 | TSHR (0.40) | L3MBTL1ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL785451 | 0.88 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL785954 | 0.88 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL786573 | 0.86 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL785287 | 0.86 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1TDP1MAPK1MAPT | |
| SCHEMBL187568 | 0.83 | RECQL (0.37) | L3MBTL1ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL186468 | 0.83 | RECQL (0.37) | L3MBTL1ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL185896 | 0.82 | RECQL (0.36) | L3MBTL1ALDH1A1TSHRTDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | L3MBTL1 272/4885ALDH1A1 834/4885TSHR 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.